Corvus Pharmaceuticals, Inc.
CRVS
$4.50
-$0.13-2.81%
| Weiss Ratings | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.96 | |||
| Price History | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 12.50% | |||
| 30-Day Total Return | -11.42% | |||
| 60-Day Total Return | -44.31% | |||
| 90-Day Total Return | -48.86% | |||
| Year to Date Total Return | -17.13% | |||
| 1-Year Total Return | 125.00% | |||
| 2-Year Total Return | 559.82% | |||
| 3-Year Total Return | 200.00% | |||
| 5-Year Total Return | 87.50% | |||
| 52-Week High % Change | -53.70% | |||
| 52-Week Low % Change | 256.15% | |||
| Price | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $10.00 | |||
| 52-Week Low Price | $1.30 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Nov 13, 2024 | |||
| Valuation | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 297.51M | |||
| Enterprise Value | 256.21M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.93 | |||
| Earnings Per Share Growth | 44.26% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 23.35 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $4.50 | |||
| Enterprise Value/EBITDA (TTM) | -10.26 | |||
| Enterprise Value/EBIT | -10.22 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 66.70M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 900 4520 | |||
| Address | 863 Mitten Road Burlingame, CA 94010 | |||
| Website | www.corvuspharma.com | |||
| Country | United States | |||
| Year Founded | 2014 | |||
| Profitability | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -28.30% | |||
| Return on Equity | -- | |||
| Income Statement | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -24.98M | |||
| EBIT (TTM) | -25.07M | |||
| Net Income (TTM) | -56.83M | |||
| Net Income Avl. to Common (TTM) | -56.83M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -570.28% | |||
| EPS Diluted (TTM) | -0.93 | |||
| EPS Diluted Growth (Q YOY) | -392.16% | |||
| Balance Sheet | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 41.65M | |||
| Cash Per Share (Q) | $0.62 | |||
| Total Current Assets (Q) | 42.92M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 12.41M | |||
| Current Ratio (Q) | 0.925 | |||
| Book Value Per Share (Q) | $0.20 | |||
| Total Assets (Q) | 58.82M | |||
| Total Current Liabilities (Q) | 46.41M | |||
| Total Debt (Q) | 354.00K | |||
| Total Liabilities (Q) | 46.41M | |||
| Total Common Equity (Q) | 12.41M | |||
| Cash Flow | CRVS - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -23.72M | |||
| Cash from Financing (TTM) | 30.42M | |||
| Net Change in Cash (TTM) | -15.43M | |||
| Levered Free Cash Flow (TTM) | 26.93M | |||
| Cash from Operations (TTM) | -22.13M | |||
